Why Remodulin?

Remodulin offers flexibility with administration

Remodulin is the most prescribed continuous pump therapy for WHO Group 1 pulmonary arterial hypertension (PAH). Seven out of 10 patients on continuous therapy are prescribed Remodulin.*

Remodulin provides medication 24 hours a day with

Remodulin subcutaneous (SC) Remodulin intravenous (IV)
Delivered via the CADD-MS® 3, a lightweight microinfusion pump that is compact, portable, and easily hidden 2 pump options: the CADD-MS® 3 and the CADD-Legacy®. Work with your doctor to determine which pump is right for you
Up to 3 days of administration with a single cassette Up to 2 days of administration with a single cassette
No mixing needed. Just draw the prescribed amount right from the vial and refill the pump Reservoirs are prepared for administration using an approved diluent
Prepared reservoirs cannot be stored for use at a later time Reservoirs can be prepared for administration and stored up to 14 days in advance when prepared with a sterile high-pH glycine diluent. Remodulin cannot be stored for 14 days when mixed with Sterile Water for Injection or Sodium Chloride Injection. The CADD-MS® 3 should not be used for premixing
*
Based on data collected from US prescribers by Guidepoint Global, LLC, for subscription data as of June 2018.
Sterile Water, Sodium Chloride Injection, or sterile high-pH glycine diluent.
Stability was demonstrated as low as 0.004 mg/mL.

Selected Important Safety Information

What are the serious side effects of Remodulin?

Learn about transitioning from Flolan® (epoprostenol sodium)

Remodulin® (treprostinil) Injection

What is Remodulin?

Remodulin is a prescription medication used to treat adults with pulmonary arterial hypertension (PAH; WHO Group 1), which is high blood pressure in the arteries of your lungs. Remodulin can reduce symptoms associated with exercise. Remodulin was studied mainly in patients with NYHA Functional Class II-IV symptoms. It is not known if Remodulin is safe and effective in children.

In people with PAH who need to switch from epoprostenol, Remodulin is approved to slow the worsening of symptoms.

Important Safety Information for Remodulin

Before you take Remodulin, tell your healthcare provider if you:

What are the serious side effects of Remodulin?

What are the possible side effects of Remodulin?

You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.

REMISIdtcJUL18

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit http://www.remodulin.com or call Customer Service at 1-877-UNITHER (1-877-864-8437).

This information is provided for an informational purpose and is not intended as treatment advice. Patients should consult a healthcare professional for treatment advice.

Important Safety Information and Indication

EXPAND ^

Remodulin® (treprostinil) Injection

What is Remodulin?

Remodulin is a prescription medication used to treat adults with pulmonary arterial hypertension (PAH; WHO Group 1), which is high blood pressure in the arteries of your lungs. Remodulin can reduce symptoms associated with exercise. Remodulin was studied mainly in patients with NYHA Functional Class II-IV symptoms. It is not known if Remodulin is safe and effective in children.

In people with PAH who need to switch from epoprostenol, Remodulin is approved to slow the worsening of symptoms.

Important Safety Information for Remodulin

Before you take Remodulin, tell your healthcare provider if you:

  • Have other medical conditions or take other medicines that may affect your use of Remodulin by increasing the risk of side effects or decreasing the drug’s effectiveness.
  • Have liver or kidney problems. Your Remodulin dose may need to be adjusted if you have liver problems.
  • Have low blood pressure or bleeding problems.
  • Are taking gemfibrozil (for high cholesterol), rifampin (for infection) or other drugs that affect liver enzymes. Your doctor may need to adjust your Remodulin dosage.
  • Are pregnant, breastfeeding, or planning to become pregnant. It is not known if Remodulin will harm your unborn baby or if Remodulin passes into your breast milk.

What are the serious side effects of Remodulin?

  • Continuous intravenous (IV) infusions of Remodulin delivered using an external infusion pump, with a tube placed in a central vein within the chest, are associated with the risk of blood stream infections and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion delivered just beneath the skin is the preferred type of delivery.
  • Worsening of PAH symptoms. Do not stop taking or greatly reduce your Remodulin dose without consulting your doctor.
  • Low blood pressure (symptomatic hypotension). If you have low blood pressure or are taking drugs that lower your blood pressure, the risk of low blood pressure is increased.
  • Bleeding problems. Remodulin may increase the risk of bleeding in people who take blood thinners (anticoagulants).

What are the possible side effects of Remodulin?

  • In clinical studies of SC infusion of Remodulin, most people experienced infusion site pain and infusion site reaction (redness, swelling, and rash). These symptoms were sometimes severe and sometimes required treatment with narcotics or discontinuation of Remodulin.
  • IV infusion of Remodulin delivered through an external pump has been associated with the risk of blood stream infections, arm swelling, tingling sensations, bruising, and pain.
  • The most common side effects seen with either SC or IV Remodulin were headache, diarrhea, nausea, rash, jaw pain, widening of the blood vessels (vasodilatation), and swelling from fluid retention (edema). These are not all the possible side effects of Remodulin. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.

REMISIdtcJUL18

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit http://www.remodulin.com or call Customer Service at 1-877-UNITHER (1-877-864-8437).

This information is provided for an informational purpose and is not intended as treatment advice. Patients should consult a healthcare professional for treatment advice.